Stockscreener 앱 받기
9.59
0.52%
-0.05
Benitec Biopharma Inc 주식(BNTC)의 최신 뉴스
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC) - Yahoo Finance
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Form 8K Benitec Biopharma Ltd ADR For: 24 September By Investing.com - Investing.com India
Benitec Biopharma appoints Ernst & Young as new auditor, replaces Baker Tilly - Investing.com
An auditor in place since 2020 is out at Benitec Biopharma (BNTC). Ernst & Young is named, pending acceptance. - Stock Titan
Benitec Biopharma FY 2026 Earnings: Revenue Flat at $0, Net Loss Widens to $45.5 Million - Sci-Tech Today
Benitec Biopharma Inc. Share PriceBNTC, RNS News, Articles, Quotes, & Charts (NASDAQ:BNTC) - Proactive financial news
Evercore Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
BENITEC BIOPHARMA Q4 2026 Earnings Preview: Recent $BNTC Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Benitec Biopharma (NASDAQ: BNTC) Reports $180M Cash Reserves as BB-301 Trial Progresses Toward 2027 Milestone - kalkinemedia.com
BNTC Maintains by Wedbush -- Price Target Raised to $17.00 - GuruFocus
Wedbush Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating - Yahoo Finance
Benitec Biopharma Files $200 Million Shelf Registration - marketscreener.com
Benitec (NASDAQ: BNTC) prepares $200M shelf that may back its lead gene therapy - Stock Titan
Benitec Biopharma Inc. FY 2026: Revenue $0 EPS $(0.98) — 10-K Summary - TradingView
Live Benitec Biopharma Inc. (BNTC) Technical Analysis - Traders Union
Benitec Biopharma reports FY2026 net loss $45.5M, cash $180.0M; advances BB-301 clinical program - tradingview.com
Benitec Reports $45.5 Million Full-Year Loss as BB-301 Trial Advances - Quiver Quantitative
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update - GlobeNewswire
Benitec Biopharma Inc. (BNTC) Debt 2026 - Stock Titan
Benitec Biopharma Inc.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Enterprise value to revenue forward of Benitec Biopharma Inc. – NASDAQ:BNTC - TradingView
Benitec (BNTC) Trading: Moves 5.71% Lower to $12.71 for the Current Session; Next Session: the $12.07 to $13.35 Range Remains in Focus in the Latest ReadingBuffered ETF - vinanet.vn
Benitec (BNTC) Levels: Posts a 4.33% Loss to $12.80 in the Latest Session; Current Setup: Price Remains Between $12.16 Support and $13.44 Resistance at the CloseVolume Spike Alerts - vinanet.vn
Benitec (BNTC) Earnings Update: The EPS Result Is Above Expectation for the Current Session; Price Reaction: The Market Price Advances 3.88% in the Latest ReadingDividend Earnings Report - dars.gov.et
Benitec (BNTC) EPS and Revenue: EPS Beats Its Estimate in Latest Trading; Latest Reaction: Shares Close 1.45% Lower on the DayPeak Earnings Alert - vinanet.vn
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Trading Systems Reacting to (BNTC) Volatility - Stock Traders Daily
BNTC Q2 2026 Earnings: Loss Narrows More Than Expected as EPS Beats Estimates by 14%Profit Guidance Range - vinanet.vn
Benitec Biopharma (BNTC) Advances 3% as Shares Test Key Resistance LevelUnusual Call Volume - Vinanet
BNTC Q2 2026 Earnings: EPS Beats Estimates Despite Revenue Absence and Share DeclineBook Value Growth - dars.gov.et
Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above 50 Day Moving AverageTime to Sell? - marketbeat.com
Benitec Biopharma Inc (BNTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth - moomoo.com
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Sahm
How Benitec Biopharma Inc. (BNTC) Affects Rotational Strategy Timing - Stock Traders Daily
Benitec Biopharma (BNTC) Slips 1.26% as Shares Test Key Support at $11.12Factor Crowding - dars.gov.et
Benitec Biopharma (NASDAQ:BNTC) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Benitec Biopharma Inc (BNTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BNTC Initiated by Wedbush -- Rating Set to Outperform with PT at $16.00 - GuruFocus
Wedbush Initiates Coverage on Benitec Biopharma (BNTC) with Outp - GuruFocus
Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target - Yahoo Finance
Benitec Biopharma Inc (BNTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Benitec Biopharma Inc (BNTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.710|Chg%:+0.240 - TradingKey
Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.540|Chg%:+0.070 - TradingKey
TradingKey - TradingKey
Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BNTC Q2 2026 Earnings: EPS Beats Estimates Despite No Revenue, Shares Edge HigherNew Analyst Coverage - careplusvn.com
BNTC|Benitec Biopharma Inc|Price:11.470|Chg%:+0.030 - TradingKey
Benitec Biopharma Inc (BNTC) Institutional Confidence - TradingKey
(BNTC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BNTC Q2 2026 Earnings: EPS Beat Estimates Despite No Revenue, Stock Edges LowerOne-Time Gain Impact - careplusvn.com
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
BNTC Q2 2026 Earnings: Narrower Loss Beats Estimates, No Revenue ReportedEBITDA Margin Trends - dars.gov.et
BNTC Q2 2026 Earnings: Narrowed Loss Beats Expectations Amid Pipeline ProgressEarnings Trend Analysis - dars.gov.et
BNTC Q2 2026 Earnings: Narrower Loss Exceeds Expectations; Stock Slightly LowerEarnings Trend Analysis - dars.gov.et
Price to sales forward of Benitec Biopharma Inc. – NASDAQ:BNTC - TradingView
3.06%
2.55%
자본화:
|
볼륨(24시간):